When: Monday, May 27, 2024 at 7:00PM EST Where: Zoom – link will be provided upon registration Faculty : Brian Leber, Juravinski Cancer Centre/McMaster University Kristjian Paulson, Cancer Care Manitoba/University of Manitoba Andre Schuh, Princess Margaret Cancer Centre/University of Toronto Objectives: Practical management issues-ongoing questions Oral arsenic: time to move forward? Canadian APL Registry- update […]
When: Monday May 6th at 7:00 PM EST Where: Zoom - link will be provided upon registration Faculty : Andre C Schuh, MD Princess Margaret Cancer Center Professor, University of Toronto Objectives: To understand the mechanism of action and importance of asparaginase in ALL treatment To compare and contrast the various asparaginase formulations available in […]
While maintenance therapy has long been a standard of care in ALL and in APL, until recently there has been little evidence to support its use in non-APL AML. In this webinar we will review recent data that have led to the approval of oral azacitidine for AML maintenance, will define the optimal use of oral azacitidine for this indication, and will discuss the evolving role of maintenance therapy in FLT3-mutated AML.
